Palavras-chave
células granulares
descompresión
enucleación
Como Citar
Resumo
El ameloblastoma es uno de los tumores benignos más agresivos y destructivos localmente de la región maxilofacial, capaz de generar grandes deformaciones faciales en un corto periodo. Sin embargo, dentro de su clasificación, la variante uniquística es considerada la menos agresiva y permite un manejo conservador de esta patología. Este artículo describe un caso clínico de una mujer de veinte años de edad, a quien se le diagnosticó un ameloblastoma uniquístico de células granulares, variante histológica poco frecuente. La lesión fue manejada de manera conservadora, realizando una descompresión durante dos meses y una enucleación con resección de los márgenes óseos. Este tratamiento disminuye la morbilidad asociada a la resección quirúrgica y se evitan grandes defectos estéticos y funcionales.
Neville B, Damm DD, Allen CM, Bouquot
JE. Oral and maxillofacial pathology.
rd ed. Vol. 1. Philadelphia:
Saunders-Elsevier; 2008.
Motahhary P, Etebarian A, Asareh F.
Granular cell type of a unicystic ameloblastoma:
An unusual case and review of
the literature. J Oral Maxillofac Pathol
JOMFP. 2014 May;18(2):331.
Robinson L, Martinez MG. Unicystic
ameloblastoma: a prognostically distinct
entity. Cancer. 1977 Nov;40(5):2278-85.
Nikolaos G. Nikitakis, Tzerbos F, Triantafyllou
K, Papadimas C, Sklavounou A.
Granular cell ameloblastoma: an unusual
histological subtype report and review of
literature. J Oral Maxillofac Res [Internet].
Jan 1 [cited 2016 Mar 28];1(4).
Disponible en: http://www.ncbi.nlm.nih.
gov/pmc/articles/PMC3886069/
Philipsen HP, Reichart PA. Unicystic
ameloblastoma: A review of 193 cases
from the literature. Oral Oncol. 1998
Sep;34(5):317-25.
Larsson A, Almerén H. Ameloblastoma
of the jaws: An analysis of a consecutive
series of all cases reported to the Swedish
Cancer Registry during 1958-1971.
Acta Pathol Microbiol Scand [A]. 1978
Sep;86A(5):337-49.
Koneru A, Hallikeri K, Nellithady GS,
Krishnapillai R, Prabhu S. Immunohistochemical
expression of calretinin in ameloblastoma, adenomatoid odontogenic
tumor, and keratocystic odontogenic
tumor: A comparative study. Appl Immunohistochem
Mol Morphol AIMM Off
Publ Soc Appl Immunohistochem. 2014
Dec;22(10):762-7.
Ghandhi D, Ayoub AF, Pogrel MA,
MacDonald G, Brocklebank LM, Moos
KF. Ameloblastoma: a surgeon’s dilemma.
J Oral Maxillofac Surg Off J
Am Assoc Oral Maxillofac Surg. 2006
Jul;64(7):1010-4.
Carlson ER, Marx RE. The ameloblastoma:
primary, curative surgical management.
J Oral Maxillofac Surg Off J
Am Assoc Oral Maxillofac Surg. 2006
Mar;64(3):484-94.
Prasad K, Lalitha RM, Ranganath K,
Srikar MV, Dexith J, Sagar P, et al. Unicystic
ameloblastoma, a distinct clinical
entity with favorable response to decompression:
Our experience of 5 cases. J
Oral Maxillofac Surg Med Pathol. 2013
Oct;25(4):328-32.
Lau SL, Samman N. Recurrence related
to treatment modalities of unicystic ameloblastoma:
a systematic review. Int J Oral
Maxillofac Surg. 2006 Aug;35(8):681-90.
Nakamura N, Higuchi Y, Tashiro H,
Ohishi M. Marsupialization of cystic
ameloblastoma: a clinical and histopathologic
study of the growth characteristics
before and after marsupialization. J Oral
Maxillofac Surg Off J Am Assoc Oral
Maxillofac Surg. 1995 Jul;53(7):748-54;
discussion 755-6.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.